ASH 2020 | FORTE: KRd versus KCd treatment for myeloma

Francesca Gay, MD, PhD, University of Turin, Turin, Italy, discusses the randomized FORTE trial (NCT02203643) investigating the survival of newly diagnosed transplant-eligible patients with multiple myeloma. The study compared progression-free survival (PFS) outcomes from three treatment regimens: carfilzomib-lenalidomide-dexamethasone (KRd) induction or carfilzomib-cyclophosphamide-dexamethasone (KCd) induction followed by autologous stem-cell transplantation (ASCT) and KRd or KCd consolidation, respectively, versus 12 cycles of KRd only (KRd12). The results showed treatment with KRd-ASCT significantly improved the PFS compared to KCd-ASCT and KRd12. A second randomization was then conducted to either KR or R maintenance therapy. KR was shown to be superior to R, resulting in a higher rate of conversion to measurable residual disease negativity and longer PFS. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.